OmniSeq News
Schoenborn named CEO at OmniSeq
June 26, 2019 Buffalo News - OmniSeq Inc., a molecular diagnostic laboratory on the Buffalo Niagara Medical Campus, has a new CEO. Margot P. Schoenborn, formerly the company's chief administrative officer, has been promoted to the position.
People in the News
June 26, 2019 GenomeWeb - OmniSeq announced today that it has appointed Margot Schoenborn to succeed Mark Gardner as the firm's CEO.
Margot Schoenborn becomes CEO of fast-growing OmniSeq
Business First - Margot Schoenborn has quite the resume. Now she gets to add yet another interesting professional experience: biotech boss. Schoenborn has been named the CEO of OmniSeq, which develops and sells molecular diagnostic tests that show cancer patients what...
OmniSeq Board Names Margot Schoenborn to Succeed Mark Gardner as CEO
June 26, 2019 BUFFALO, N.Y., June 26, 2019 (GLOBE NEWSWIRE) -- OmniSeq, Inc. named Margot P. Schoenborn to succeed Mark Gardner as the chief executive officer of the molecular diagnostics and precision medicine company.
OmniSeq and LabCorp Extend Exclusive Distribution Pact and Complete Follow-On Investment Agreement
BUFFALO, N.Y., April 23, 2019 (GLOBE NEWSWIRE) -- OmniSeq®, a CAP-accredited, molecular diagnostics spin-out of Roswell Park Comprehensive Cancer Center, and LabCorp® (NYSE: LH), a leading global life sciences company, announced today an extension of their...
OmniSeq & LabCorp Launch OmniSeq Advance℠ Assay
New test combines both targeted therapy and immune-oncology biomarkers in a single test with 99% actionability, providing benefits for the treatment of patients and the development of new therapies.ASCO, CHICAGO, ILLINOIS – June 1, 2018 – OmniSeq® , a CAP accredited,...
Hitachi High-Tech Participates in OmniSeq Series B and Secures Japanese Distribution Rights
BUFFALO, NEW YORK – April 12, 2018 – OmniSeq® , a molecular diagnostics subsidiary of the Roswell Park Comprehensive Cancer Center, announced today Hitachi High-Technologies Corporation (TOKYO: 8036, Hitachi High-Tech)’s participation in OmniSeq’s Series B financing...
OmniSeq & LabCorp Launch Tumor-Only MSI NGS Assay
BUFFALO, NEW YORK – April 16, 2018 – OmniSeq®, a molecular diagnostics subsidiary of the Roswell Park Comprehensive Cancer Center, and LabCorp® (NYSE: LH), a leading global life sciences company, announced today the commercial launch of OmniSeq MSI NGS, a tumor-only,...
OmniSeq Receives CAP Accreditation and Publishes Analytical Validation Paper
Important Achievements Validate OmniSeq’s High Quality Laboratory Practices and Immune Report Card Assay Buffalo, NY – NOVEMBER 9, 2017 – OmniSeq, Inc., a molecular diagnostics subsidiary of the Roswell Park Cancer Institute, announced today that it...
OmniSeq and LabCorp Sign Exclusive Distribution Agreement and Series B Funding Commitment
Marcia Eisenberg, Chief Scientific Officer of LabCorp Diagnostics, to Join OmniSeq’s Board of Directors BUFFALO, N.Y., Aug. 21, 2017 (GLOBE NEWSWIRE) -- OmniSeq, Inc., a molecular diagnostics subsidiary of the Roswell Park Cancer Institute, announced today...
Follow Us on Twitter
Congrats to Mary Nesline on her paper newly published in @OncotargetJrnl on Tuesday!
https://tinyurl.com/yyrlvd7l
OmniSeq Board Names Margot Schoenborn to Succeed Mark Gardner as CEO http://bit.ly/2X6yLoR
OmniSeq is grateful for the continued support and partnership with @LABCORP . Together, we aim to expand patient access to market leading NGS diagnostics throughout the country. #NGS #TargetedTherapy #Immunotherapy #Diagnostics
https://www.globenewswire.com/news-release/2019/04/23/1807811/0/en/OmniSeq-and-LabCorp-Extend-Exclusive-Distribution-Pact-and-Complete-Follow-On-Investment-Agreement.html
Thank you Wired Magazine and Empire State Development for featuring OmniSeq as a Western New York success story! #ngs #immunotherapy
How One NY Company Is Changing Cancer Treatment
https://www.wired.com/brandlab/2019/03/new-york-state-development-omniseq/